Skip to main content

Table 4 Treatments and outcomes in patients with spontaneous bacterial peritonitis caused by Enterobacter species and Escherichia coli

From: Erratum to: Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study

Variable

Enterobacter SBP (n = 32)

E. coli SBP (n = 128)

P

Initial empirical antimicrobial agent

 Cefotaxime

27 (84.4)

116 (90.6)

0.31

 Imipenem or meropenem

4 (12.4)

9 (7.0)

 

 Cefazolin

1 (3.1)

0 (0)

 

 Ceftazidime

0 (0)

1 (0.8)

 

 Cefepime

0 (0)

1 (0.8)

 

 Levofloxacin

0 (0)

1 (0.8)

 

Appropriateness of initial therapy

27 (87.1)

109 (87.2)

1.00

Initial response to empirical treatmenta

26/32 (81.3)

95/117 (81.2)

0.995

Emergence of resistance during third-generation cephalosporin treatment

1/23 (4.3)

0/98 (0)

0.19

Duration of hospitalization, median days (IQR)

 Overall

20 (11–31)

16 (10–26)

0.28

 Survivors

22 (12–31)

16 (11–26)

0.41

Duration of antimicrobial use, median days (IQR)

 Overall

15 (11–25)

13 (8–16)

0.02

 Survivors

16 (13–29)

13 (10–16)

0.01

ICU care during admission

2 (6.2)

19 (14.8)

0.25

Mortality

 14-day mortality

7 (21.9)

25 (19.5)

0.77

 30-day mortality

12 (37.5)

37 (28.9)

0.35

 In-hospital mortality

12 (37.5)

28 (21.9)

0.07

  1. Values are n (%) unless otherwise indicated. IQR interquartile range, ICU intensive care unit
  2. aAscitic neutrophil decrease >25 % observed 48–72 h after initiating antimicrobials